FHTX Q3 2021 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$322M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41,000-77.1% YoY

Gross Profit

-$20M-49885.4% margin

Operating Income

-$26M-64051.2% margin

Net Income

-$26M-63609.8% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

-85.3%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$186M

Total Liabilities

$105M

Stockholders' Equity

$81M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41,000	$179,000	-77.1%
Gross Profit	-$20M	$179,000	-11526.3%
Operating Income	-$26M	-$18M	-42.0%
Net Income	-$26M	-$18M	-42.0%